摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-溴-2-甲氧基苯甲醛 | 88275-87-0

中文名称
3-溴-2-甲氧基苯甲醛
中文别名
——
英文名称
3-bromo-2-methoxybenzaldehyde
英文别名
——
3-溴-2-甲氧基苯甲醛化学式
CAS
88275-87-0
化学式
C8H7BrO2
mdl
MFCD09834811
分子量
215.046
InChiKey
SZDPZQAPHXPVCN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    282.3±20.0 °C(Predicted)
  • 密度:
    1.522±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.125
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2913000090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335
  • 储存条件:
    2-8℃,在惰性气体氛围下

SDS

SDS:29b042f41c98155405258835d5e9a2bd
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 3-Bromo-2-methoxybenzaldehyde
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 3-Bromo-2-methoxybenzaldehyde
CAS number: 88275-87-0

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H7BrO2
Molecular weight: 215.0

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Linear diarylheptanoids as potential anticancer therapeutics: synthesis, biological evaluation, and structure–activity relationship studies
    作者:A. F. M. Motiur Rahman、Yang Lu、Hwa-Jong Lee、Hyunji Jo、Wencui Yin、Mohammad Sayed Alam、Hyochang Cha、Adnan A. Kadi、Youngjoo Kwon、Yurngdong Jahng
    DOI:10.1007/s12272-018-1004-8
    日期:2018.12
    detrimental action of the drug toward the intestinal flora, a series of linear diarylheptanoids (LDHs) were designed and synthesized in 7 steps with good-to-moderate yields. All synthesized compounds were evaluated for their antibacterial, antiproliferative, and topoisomerase-I and -IIα inhibitory activity. Overall, all compounds showed little to no activity against the bacterial strains tested. Most of the
    为了开发有效的抗癌疗法,对癌细胞具有更大的选择性并减少副作用,例如由于药物对肠道菌群的有害作用引起的催吐作用,设计并分 7 个步骤合成了一系列线性二芳基庚烷 (LDH)产量良好至中等。评估了所有合成化合物的抗菌、抗增殖和拓扑异构酶-I 和-IIα 抑制活性。总体而言,所有化合物对所测试的细菌菌株几乎没有活性。大多数合成的化合物对人乳腺癌细胞系(T47D)显示出良好的抗增殖活性;具体而言,化合物 6a、6d、7j 和 7e 的 IC50 值分别为 0.09、0.64、0.67 和 0.99 μM。在测试的化合物中,7b 抑制了 topo-I 9。在 100 μM 的浓度下,3%(喜树碱 68.8%)、7e 和 7h 分别抑制了 38.4% 和 47.4%(依托泊苷 76.9%)的 topo-IIα。这些结果表明,可以通过减少对不同微生物的抑制作用来提高对癌细胞的选择性,从而获得一组有前景的抗癌药物。
  • Redox‐Neutral Coupling between Two C(sp <sup>3</sup> )−H Bonds Enabled by 1,4‐Palladium Shift for the Synthesis of Fused Heterocycles
    作者:Ronan Rocaboy、Ioannis Anastasiou、Olivier Baudoin
    DOI:10.1002/anie.201908460
    日期:2019.10.7
    secondary C-H bonds, which are adjacent to an oxygen or nitrogen atom on one side, and benzylic or adjacent to a carbonyl group on the other side. A variety of valuable fused heterocycles were obtained from easily accessible ortho-bromophenol and aniline precursors. The second C-H bond cleavage was successfully replaced with carbonyl insertion to generate other types of C(sp3 )-C(sp3 ) bonds.
    通过从三取代的芳基溴化物进行的1,4-Pd转移,可以使两个C(sp3)-H键形成一个C(sp3)-C(sp3)键进行分子内偶联。与大多数C(sp3)-C(sp3)交叉脱氢偶联相反,该反应在氧化还原中性条件下进行,其中C-Br键充当内部氧化剂。此外,它允许两个中等酸性的伯或仲CH键之间的偶联,其在一侧与氧或氮原子相邻,而在另一侧为苄基或与羰基相邻。从易于获得的邻溴苯酚和苯胺前体中获得了各种有价值的稠合杂环。第二个CH键裂解成功地被羰基插入取代,以生成其他类型的C(sp3)-C(sp3)键。
  • [EN] PHTHALAZINE DERIVATIVES AS INHIBITORS OF PARP1, PARP2 AND/OR TUBULIN USEFUL FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE PHTALAZINE UTILES EN TANT QU'INHIBITEURS DE PARP1, PARP2 ET/OU DE TUBULINE DANS LE TRAITEMENT DU CANCER
    申请人:UNIV CALIFORNIA
    公开号:WO2017223516A1
    公开(公告)日:2017-12-28
    The application relates to phthalazine derivatives of formula (I) which are inhibitors of PARP1, PARP2 and/or tubulin and thus useful for the treatment of cancer. Also disclosed are pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.
    该应用涉及公式(I)的邻苯二氮杂环衍生物,它们是PARP1、PARP2和/或微管的抑制剂,因此对于癌症的治疗是有用的。还披露了含有这些化合物的药物配方,以及这些化合物与至少一种额外治疗剂的组合。
  • Thrombopoietin mimetics
    申请人:——
    公开号:US20030083361A1
    公开(公告)日:2003-05-01
    Invented are non-peptide TPO mimetics. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected substituted naphthimidazole derivative.
    发明了非肽类TPO类似物。还发明了一种治疗血小板减少症的方法,包括在需要的哺乳动物,包括人类中,向该哺乳动物施用所选取代萘咪唑衍生物的有效量。
  • First Total Synthesis of 7-Isovaleryloxy-8-methoxygirinimbine
    作者:Christian Brütting、Arndt Schmidt、Olga Kataeva、Hans-Joachim Knölker
    DOI:10.1055/s-0037-1609717
    日期:2018.7
    Abstract We describe the first total synthesis of the pyrano[3,2-a]carbazole alkaloid 7-isovaleryloxy-8-methoxygirinimbine, using a palladium(II)-catalyzed double C–H-bond activation for construction of the carbazole framework and a phenylboronic acid catalyzed annulation of the pyran ring as key steps. We describe the first total synthesis of the pyrano[3,2-a]carbazole alkaloid 7-isovaleryloxy-8-methoxygirinimbine
    摘要 我们描述了吡喃并[3,2- a ]咔唑生物碱7-异戊酰氧基-8-甲氧基吉里宁的第一个全合成,使用钯(II)催化的双CH键结合构造咔唑骨架和苯硼酸酸催化吡喃环的环化为关键步骤。 我们描述了吡喃并[3,2- a ]咔唑生物碱7-异戊酰氧基-8-甲氧基吉里宁的第一个全合成,使用钯(II)催化的双CH键结合构造咔唑骨架和苯硼酸酸催化吡喃环的环化为关键步骤。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐